IF YOU HAVE PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) OR MYCOSIS FUNGOIDES (MF), YOU CAN HELP BY COMPLETING OUR SURVEY
Lymphoma Canada and the Canadian Skin Patient Alliance are preparing a submission for the panCanadian Oncology Drug Review (pCODR) so that CTCL patients in Canada can gain access to the following therapy: Brentuximab-vedotin (ADCETRIS) for relapsed/refractory PCALCL or CD30+ MF
The results of the survey will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, April 10, 2020 and should only take 10 minutes of your time.
You may access the survey by clicking the link below:
